Rheumnow Podcast

Dr.Jack Cush reviews the hot item takeaways from last weeks RheumNow.Live 2026 Diet & Obesity Management in Rheumatology - Uzma Haque, MD Mitigating risk for Rheum patients undergoing orthopedic surgery - Susan Goodman, MD Paradoxical skin reactions – Dr. Joseph Merola Mortality in RA  - Elena Myasoedova, MD The Mucosal Hypothesis to RA - Kristin Demourelle, MD Advances in ILD - Jeffrey Sparks, MD Seronegative vs. Seropositive RA - Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory news from this past week on RheumNow.com

The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects.  Features Dr. Jack Cush, Editor at RheumNow.com.  SHOW NOTES Lupus Accelerating Breakthroughs Consortium commissioned a stakeholders group (including the FDA) to assess drug development in Cutaneous lupus CLE), and they have endorsed CLASI (CLE Dz Area & Severity Index) as the outcome measure for CLE clinical trials. https://t.co/q7If97AHBa PAPA Syndrome: When Sterile Inflammation Mimics Infection (Pyogenic Arthritis, Pyoderma gangrenosum, Acne) •A rare monogenic autoinflammatory disease •Caused by gain-of-function mutations in PSTPIP1 🧠 Pathophysiology •Mutant PSTPIP1 - increased interaction with pyrin https://t.co/tJ4INdgfky Turkish study of 128 Psoriatics (62 PSO, 66 PsA) found more periodontitis in PsA vs PSO (47% vs 31%; P=.058). Assoc. w/ Signif. higher levels of Dz activity seen for PSO (CPDAI: OR 1.38; P = .001) & enthesitis (MASES: OR 1.39; P  .001) if periodontitis present in PsA patients. https://t.co/d8OfarFWeG Subcutaneous Anifrolumab in SLE Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. https://t.co/EzaqS5q096 Did you know theres a Subcutaneous (SC) rituximab (Hycela)? Its same RTX but combined w/ hyaluronidase, faster 5-7 minute injection Vs hours for IV RTX. FDA approved 2017 for Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL). Give 1st dose IV, then use SC RTX. https://t.co/piQ2ZhAOyf German psoriasis registry PsoBest reports on 595 Rx w/ apremilast (417 APR monotherapy). Compared to Ptx Rx w/ other DMARDs/biologic drugs, APR pts higher age, more comorbidities. Nonserious AEs: ineffectiveness (14%), diarrhea (9%), nausea (7%), HA (6%). https://t.co/TviJmM7Fr9 https://t.co/tY89oHgUgV DMARD Responses in Localized Scleroderma – MMF = MTX ~114 pts Advanced Practitioner Biologic Prescriptions for Psoriasis Advanced practice clinicians (APCs; nurse practitioners and physician assistants) deliver a large share of US dermatologic care, accounting for 37% of clinicians and 27% of dermatology visits by 2020. A current JAMA https://t.co/3NtntmpSPV GLP-1 Agonist plus IL-17 Inhibition in Obese Psoriatic Arthritis Lilly announced the topline results from its phase 3b "TOGETHER PsA" trial, showing that the combination use of ixekizumab (Taltz) and tirzepatide (Zepbound) was superior to IXE alone, yielding both significant https://t.co/8fOXWULH7w

Dr. Jack Cush reviews the news and journal reports from RheumNow.com Top 5 reasons to attend RheumNow Live 2026 1. Its cold and far, but you can be there virtually, online 2. Ffull access to handouts, slides & downloads 3. Saturday concert with Colin Boyd  4. Rohit Agarwal does TWO STEP talks! 5. Download 400+ rheumatology review Questions REGISTER at - RheumNow.live  

Join us for our next webinar: Focus on Guidelines. Panelists will discuss their approaches to a range of difficult cases in multiple areas, including rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis and vasculitis, and discuss how they apply the guidelines in everyday practice. You’ll hear different perspectives and practical tips you can use in clinic. Panelists: Audrey Gibson, PA-C Benjamin A. Smith, PA-C Jack Cush, MD Following the discussion, join a live Q & A with the panelists. Register now to reserve your spot!  This is our second Tuesday Night Rheumatology this month as part of our Mission: APP Partners in Care campaign

Dr. Jack Cush reviews the news and reports from the past two weeks on RheumNow.Com

Dr. Jack Cush reviews rheumatology's highlights, advances and noteworthy trends from the past year - 2025!

1- Sex & the Rheum Patient (12:17) 2- Pain Management (17.58)  3- Lifestyle (15.38)

This podcast is part one of the Mission: APP Partners in Care Therapeutic Update Series called Underserved and under-treated. This podcast includes videos from: Daric Mueller, PA-C, Rachel Busch-Feuer, DNP, Betsy Kirchner, DNP, Lindsay Tom, PA-C and Vanessa Hill, NP-C

Dr. Jack Cush reviews the news, announcements and journal articles from this past week on RheumNow.com.  More on Variable bendability, a better way to treat RA, and a novel advance for GLP1a in PsA; and 2026 Resolutions!

Features Dr. Jack Cush

Panelists: Vanessa Hill, NP-C Lindsay Tom, PA-C Barb Slusher Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Who would've thunk - a PsA FMF connection? Labs to diagnose SSc-ILD? IgA-RF may be important or RZV may not work in JAK inhibitor treated patients?

Join us for our third webinar this month, discussing APP Controversies and Misconceptions. Panelists will cover a range of topics, including APP roles impact; models of care; independence; seeing new patients and complex cases; and more. Panelists: Daric A. Mueller, PA-C Lisa Carnago, MSN, FNP-C, RN Jack Cush, MD

Dr. Jack Cush reviews the news, journal and regulatory reports from this past week on RheumNow.com.  B cell drugs in SLE and ITP, biomarkers in GCA & PSS and great videos by APPs.

Drs. Jack Cush and Artie Kavanaugh preview the upcoming RNL 2026 meeting in Dallas, TX on February 7 & 8, 2026. Register at RheumNow.Live Below is the program: Saturday, February 7, 2026, 7:50 - 8:00 am Welcome & Introductions Drs. Cush and Kavanaugh 8:00 - 10:00 am POD I - Rheumatoid Arthritis: Achieving Better Outcomes 8:00 – 8:30 am Mortality in RA: A Story of Decline, Delay, or Plateau? Elena Myasoedova, MD 8:30 – 9:00 am The Mucosal Hypothesis of Rheumatoid Arthritis Kristen Demoruelle, MD 9:00 – 9:30 am ILD in RA – Recent Advances Jeffrey Sparks, MD 9:30 – 10:00 am Rheumatoid arthritis Faculty Q&A 10:00 - 10:15 am STEP 1: Placebos in Rheumatology Andreas Kerschbaumer, MD 10:15 -10:30 am STEP 2: Disease Modification in Osteoarthritis Tuhina Neogi, MD PhD 10:30 – 11:05 Break 11:05 - 12:10 pm POD II – Advancing Practice 11:05 – 11:30 am Obesity & Inflammation: Weight Management in Rheumatology Uzma Haque, MD 11:30 - 11:55 am Mitigating risk in Rheum Pts undergoing surgery Susan Goodman, MD 11:55 -12:10 pm Practice Panel Faculty Q&A 12:10 – 1:00pm Lunch 1:00 – 3:00 pm POD III – Decisions in Psoriatic Arthritis 1:00 - 1:30 pm Paradoxical Psoriasis and Strange Reactions Joseph Merola, MD 1:30 - 2:00 pm Why Do Plain X rays in Psoriatic Arthritis Arthur Kavanaugh, MD 2:00 - 2:30 pm IL-23 vs IL-17 inhibitors in PsA Andre Ribero, MD 2:30 - 3:00 pm Past, Present & Future of Gout Robert Terkeltaub, MD 3:00 - 3:30 pm Psoriatic Faculty Q&A 3:30 - 4:05 pm Break 4:05 - 4:20 pm STEP 3: Helicobacter Pylori update Byron Cryer, MD 4:20 - 4:35 pm STEP 4: History of Gout Robert Terkeltaub, MD 4:35 – 5:15 pm Keynote Address: 50 Years of Osteoporosis Michael McClung, MD 5:30 – 7:00 pm Reception Sunday, February 8, 2026 Day TOPIC Speaker 7:50-8:00 am Welcome & Introductions Drs. Cush and Kavanaugh 8:00 - 10:00 am POD IV – Staying Ahead of Spondyloarthritis 8:00 – 8:30 am Diagnosing Axial Spondyloarthritis in 2026 Denis Poddubnyy, MD 8:30 – 9:00 am Spondyloarthritis Complications Jessica Walsh, MD 9:00 – 9:30 am 2026 Advances in Spondyloarthritis Catherine Bakewell, MD 9:30 – 10:00 am Spondyloarthritis Faculty Q&A 10:00 – 10:15 am STEP 5: Asymptomatic Elevation of CK Rojit Agarwal, MD MS 10:15 – 10:30 am STEP 6: Update on Myositis Antibodies Rojit Agarwal, MD MS 10:30 – 11:05 am Break 11:05 – 12:10 am POD V – Highlights in Autoimmune Disease 11:05 - 11:35 am SMILE Study – Hydroxychloroquine in ANA+ Arthralgia Nancy Olsen, MD 11:35 – 12:05 am Sjogren's Treatment Landscape in 2026 Matthew Baker, MD 12:05 - 12:20 pm Autoimmune Faculty Q&A 12:20 – 1:25 pm POD VI - Large & Small Vessel Vasculitis 12:20 – 12:45 pm Embracing Relapses in PMR and GCA Michael Putman, MD 12:45 - 1:10 pm Small vessel vasculitis Clay Cockerell, MD 1:10 - 1:25 pm Vasculitis Faculty Q&A 1:30 pm Adjourn

QD300: Flare or Beware (featuring Lindsay Tom, PA-C and Phong Nguyen, MD) QD301: CAR-T Cell Therapy for Lupus  (featuring Philip Mease, MD and Cayla Alexander, DNP) QD302: Unweanable PMR  (featuring Jack Cush, MD, and Leilani Law, APN) QD303: Weakness with Fibromyalgia  (featuring Jack Cush, MD, and Leilani Law, APN)

Dr. Jack Cush reviews the news and journal reports from RheumNow.com, including info on scleroderma, dermatomyositis and malignancy, rheumatologist and APP salaries concerns.

Watch our kickoff webinar for this month's Mission: APP — Partners in Care campaign. Our panel of rheumatologists and experienced advanced practice providers share insights into hiring, onboarding, training, compensation, and more. Panelists: Philip Mease, MD Cayla Alexander, DNP, ARNP Kori Dewing, DNP, ANP-BC, ARNP Jack Cush, MD, Moderator

Dr. Jack Cush reviews the news and reports from this past week on RheumNow.com, including reports on FDA resurrections, FM seasonal worsening, and do you fight switch or swap biologics in PsA TNFi nonresponders?